A letter to members of the UCSD Moores Cancer Center

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

HHS earlier this week rolled out a cluster of initiatives related to simplifying clinical trials, presenting these measures as a government-wide effort to maintain America’s leadership in early-stage drug development.

RWJBarnabas Health, Rutgers Cancer Institute open Melchiorre Cancer Center in North Jersey

RWJBarnabas Health and Rutgers Cancer Institute have opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center. The cancer center, located on the campus of Cooperman Barnabas Medical Center in Livingston, is a five-story, 137,000-square-foot, $225 million, outpatient facility for oncology services.

June 26, 2026

Vol.52 No.25

In Brief

UC San Diego’s Natasha Martin awarded $5.6M NIDA Avant-Garde Award to prevent HIV, hepatitis C, and overdose

Natasha Martin, professor and vice chief of Global Public Health in the Division of Infectious Diseases and Global Public Health at UC San Diego School of Medicine, has been awarded a five-year, $5.6 million Avant-Garde Award from the National Institute on Drug Abuse.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

Clinical Trials & Tribulations

What NHS-Galleri taught us—and what it didn’t

On May 30, GRAIL reported the full results of the NHS-Galleri trial in an oral presentation at the ASCO Annual Meeting.

June 18, 2026

Vol.52 No.24

By Scott D. Ramsey and Ruth Etzioni

Clinical Trials & Tribulations

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening.

June 18, 2026

Vol.52 No.24

By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari

A letter to members of the UCSD Moores Cancer Center

YOU MAY BE INTERESTED IN

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

RWJBarnabas Health, Rutgers Cancer Institute open Melchiorre Cancer Center in North Jersey

UC San Diego’s Natasha Martin awarded $5.6M NIDA Avant-Garde Award to prevent HIV, hepatitis C, and overdose

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

What NHS-Galleri taught us—and what it didn’t

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

Renew today!

Subscriber content

Never miss an issue!

Login